Prothena Corporation plc (PRTA)
Prothena (PRTA) Up 17.6% Since Last Earnings Report: Can It Continue?
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?
Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates
Prothena (PRTA) came out with a quarterly loss of $1.86 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to earnings of $1.22 per share a year ago.
PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?
Prothena slashes 63% of its workforce and axes birtamimab after trial failure, reshaping its pipeline and financial outlook. Shares plunge 53.5% YTD.
Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down
PRTA shares drop 22% after ending birtamimab development as a phase III study fails to meet primary or secondary endpoints in AL amyloidosis.
Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025
PRTA posts a wider-than-expected first-quarter loss. Investors will focus on important readouts on birtamimab and PRX012 later in 2025.
Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates
Prothena (PRTA) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to loss of $1.34 per share a year ago.
Prothena Q4 Earnings Miss Estimates, Pipeline Progress in Focus
PRTA posts a wider-than-expected fourth-quarter loss. However, it reports encouraging pipeline progress for the quarter.
Prothena Corporation plc (PRTA) Q4 2024 Earnings Call Transcript
Prothena Corporation plc (NASDAQ:PRTA ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Mark Johnson - Vice President of Investor Relations Gene Kinney - President and Chief Executive Officer Chad Swanson - Chief Development Officer Tran Nguyen - Chief Financial Officer and Chief Strategy Officer Brandon Smith - Chief Operating Officer Conference Call Participants Emma Seymour - Piper Sandler Jay Olson - Oppenheimer Umer Raffat - Evercore Charles Duncan - Cantor Fitzgerald Jason Butler - Citizens JMP Michael Yee - Jefferies Rudy Li - Chardan Tazeen Ahmad - Bank of America Brian Abrahams - RBC Capital Markets Operator Good day, ladies and gentlemen, and welcome to the Prothena Biosciences Fourth Quarter and Full Year 2024 Financial Results Conference Call. My name is Pam, and I will be your coordinator for today.
Prothena (PRTA) Reports Q4 Loss, Misses Revenue Estimates
Prothena (PRTA) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $1.26 per share a year ago.
Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report?
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?
Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus
PRTA posts a narrower-than-expected loss in the third quarter. The company also reports encouraging pipeline progress for the quarter.
Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates
Prothena (PRTA) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.18. This compares to earnings of $0.38 per share a year ago.
